Nadia R P W Hutten

TL;DR: It is demonstrated that psilocybin induced region-dependent alterations in glutamate, which predicted distortions in the subjective experience of one’s self (ego dissolution), which may provide a neurochemical basis for therapeutic effects as witnessed in ongoing clinical trials.

TL;DR: The majority of users microdosed to enhance performance, but the main reason to have stopped microdosing was that it was not effective, and future experimental placebo-controlled studies are needed to test whether performance enhancement can be quantified and to assess potential negative effects after longer term microdoses.

TL;DR: The finding that LSD acutely increases BDNF levels warrants studies in patient populations, based on preclinical evidence for psychedelic-induced neuroplasticity in humans.

TL;DR: Overall, the present study demonstrated selective, beneficial effects of low doses of LSD on mood and cognition in the majority of observations, and the minimal LSD dose at which subjective and performance effects are notable is 5 mcg and the most apparent effects were visible after 20 mcg.

TL;DR: This double-blind, placebo-controlled study suggests that THC elicits subjective and cognitive alterations via increased striatal dopaminergic activity and loss of corticostriatal connectivity, which is associated with an increase in striatal glutamate.